Hemophilia A | Treatment Algorithms: Claims Data Analysis | US | 2024
Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by a deficiency in factor VIII. Currently, FVIII recombinant therapies, bypass agents, Hemlibra, and vasopressin receptor agonists are used in the management of hemophilia A. Hemlibra has been a transformative treatment for patients with hemophilia A by offering improved treatment outcomes, reduced dosing burden, and convenient subcutaneous administration. In this report, we closely examine how key current therapies are being used in the treatment of newly diagnosed and recently treated hemophilia A patients in the United States.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed hemophilia A patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed hemophilia A patients?
- How has Hemlibra been integrated into the treatment algorithm, and what is its source of business?
- What percentage of hemophilia A patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within two years of diagnosis?
- What percentage of hemophilia A patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Markets covered: United States
Key companies: Baxter HealthCare, Novo Nordisk, BioMarin, Takeda, Sanofi, Genentech
Key drugs: Hemlibra, Roctavian, Altuviiio, Eloctate, Esperoct, Adynovate, Jivi, SHL FVIIIs
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Key feature
Dashboard featuring interactive visuals, easy navigation, and expanded analyses
